, Volume 4, Issue 4, pp 666–675

Modulating co-stimulation

Review Article

DOI: 10.1016/j.nurt.2007.07.006

Cite this article as:
Viglietta, V. & Khoury, S.J. Neurotherapeutics (2007) 4: 666. doi:10.1016/j.nurt.2007.07.006


The modulation of co-stimulatory pathways represents a novel therapeutic strategy to regulate autoimmune diseases. Auto-reactive CD4+ T cells play a critical role in initiating the immune response leading to inflammation and autoimmune diseases. Blocking co-stimulatory signals prevents T-cell activation, thus diminishing autoimmune responses and possibly preventing the progression of autoimmune disease. Blockade of several co-stimulatory pathways has been investigated in animal models and has led to clinical trials testing specific blocking agents in humans. In this review we will describe the role of co-stimulatory pathways, primarily the CD28-B7 pathway, in autoimmune diseases, and we will present in vivo and in vitro studies supporting the efficacy of co-stimulation blockade in animal models of autoimmune disease. Finally, we will discuss the clinical therapeutic efficacy of blocking monoclonal antibodies in preventing or reducing auto-antigen driven T-cell activation in humans with particular attention to the CD28/B7 pathway. Inhibiting co-stimulatory molecule interactions by using monoclonal antibodies seems to be an original approach to regulate autoimmune diseases in humans.

Key Words

T-cell activation CD28/B7 molecules co-stimulation blockade CT1A-4 Ig EAE/MS monoclonal antibody (mAb) 
Download to read the full article text

Copyright information

© Springer New York 2007

Authors and Affiliations

  1. 1.Clinical Immunology Laboratory, Center for Neurologic DiseasesBrigham and Women’s Hospital and Harvard Medical SchoolBoston
  2. 2.Center for Neurologic DiseasesHarvard Institutes of MedicineBoston

Personalised recommendations